Market-Moving News for September 26th
Portfolio Pulse from ryanfaloona@benzinga.com
Ginkgo Bioworks announced a multi-target RNA discovery collaboration with Pfizer. ShiftPixy announced its reverse stock 1-for-24 split effective date, causing its shares to trade higher. Cardiff Oncology announced positive clinical data in pancreatic cancer and small cell lung cancer, including single-agent activity from Onvansertib monotherapy.
September 27, 2023 | 12:40 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cardiff Oncology announced positive clinical data in pancreatic cancer and small cell lung cancer, including single-agent activity from Onvansertib monotherapy.
The announcement of positive clinical data indicates progress in Cardiff Oncology's research, which could lead to the development of new cancer treatments. This is likely to increase the company's stock value.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100
POSITIVE IMPACT
Ginkgo Bioworks announced a multi-target RNA discovery collaboration with Pfizer.
The collaboration with Pfizer, a major pharmaceutical company, could lead to the discovery of new treatments, which would likely increase Ginkgo Bioworks' stock value.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
ShiftPixy announced its reverse stock 1-for-24 split effective date, causing its shares to trade higher.
The announcement of the reverse stock split has already caused ShiftPixy's shares to trade higher. This trend may continue in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100